Table 4.
Phase II trials of epidermal growth factor receptor inhibitors in hepatocellular carcinoma.
| Year | Patients N | RR (%) | Median PFS (Months) | Median OS (Months) | |
|---|---|---|---|---|---|
| Erlotinib [Philip et al. 2005] | 2005 | 38 | 9 | 3.2 | 13 |
| Erlotinib [Thomas et al. 2007] | 2007 | 40 | 0 | 3.1 | 6.3 |
| Lapatinib [Ramanathan et al. 2009] | 2009 | 40 | 5 | 2.3 | 6.2 |
| Lapatinib [Bekaii-Saab et al. 2009] | 2009 | 26 | 0 | 1.9 | 12.6 |
| Cetuximab [Gruenwald et al. 2007] | 2007 | 32 | 0 | 2 | - |
| Cetuximab [Zhu et al. 2007] | 2007 | 30 | 0 | 1.4 | 9.6 |
Abbreviations: OS, overall survival; PFS, progression-free survival; RR, response rate